Mathematical modeling in cancer drug discovery

Drug Discovery Today

Volumn 19, Issue 2, 2014, Pages 145-150

  Wang, Zhihui ^a   Deisboeck, Thomas S ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b ThinkMotu LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER PATIENT; DRUG DEVELOPMENT; EXPERIMENT; EXPERIMENT MODELING EXPERIMENT; HUMAN; MATHEMATICAL MODEL; MODEL; MULTISCALE MODELING; NETWORK BASED MODELING; PHYSICAL PARAMETERS; PREDICTIVE VALUE; REVIEW; TRANSLATIONAL MODELING; ANIMAL; DRUG DESIGN; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; THEORETICAL MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MODELS, THEORETICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84895922732     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.06.015     Document Type: Review

References (60)

1. M.E. Cartwright et al. Proof of concept: a PhRMA position paper with recommendations for best practice Clin. Pharmacol. Ther. 87 2010 278 285
2. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715
3. S.M. Paul et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
4. T.S. Deisboeck Personalizing medicine: a systems biology perspective Mol. Syst. Biol. 5 2009 249
5. E.C. Butcher et al. Systems biology in drug discovery Nat. Biotechnol. 22 2004 1253 1259
6. A.S. Popel, and P.J. Hunter Systems biology and physiome projects Wiley Interdiscip. Rev. Syst. Biol. Med. 1 2009 153 158
7. E. Wang et al. Cancer systems biology: exploring cancer-associated genes on cellular networks Cell. Mol. Life Sci. 64 2007 1752 1762
8. Z. Wang et al. Accelerating cancer systems biology research through Semantic Web technology Wiley Interdiscip. Rev. Syst. Biol. Med. 5 2013 135 151
9. G.H. Fernald et al. Bioinformatics challenges for personalized medicine Bioinformatics 27 2011 1741 1748
10. R. Siegel et al. Cancer statistics, 2012 CA Cancer J. Clin. 62 2012 10 29
11. E. Whitmore Development of FDA-Regulated Medical Products: A Translational Approach 2nd edn 2012 ASQ Quality Press
12. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
13. G.R. Zimmermann et al. Multi-target therapeutics: when the whole is greater than the sum of the parts Drug Discov. Today 12 2007 34 42
14. E.L. Leung et al. Network-based drug discovery by integrating systems biology and computational technologies Brief. Bioinform. 2013 [Epub ahead of print]
15. M. Vidal et al. Interactome networks and human disease Cell 144 2011 986 998
16. T.S. Deisboeck et al. Multiscale cancer modeling Annu. Rev. Biomed. Eng. 13 2011 127 155
17. V. Cristini, and J.S. Lowengrub Multiscale Modeling of Cancer: An Integrated Experimental and Mathematical Modeling Approach 2010 Cambridge University Press
18. A.L. Hopkins Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 4 2008 682 690
19. M.A. Yildirim et al. Drug-target network Nat. Biotechnol. 25 2007 1119 1126
20. P. Tracqui Biophysical models of tumour growth Rep. Progr. Phys. 72 2009 056701
21. E.K. Silverman, and J. Loscalzo Developing new drug treatments in the era of network medicine Clin. Pharmacol. Ther. 93 2013 26 28
22. T. Pawson, and R. Linding Network medicine FEBS Lett. 582 2008 1266 1270
23. A. Awan et al. Regulatory network motifs and hotspots of cancer genes in a mammalian cellular signalling network IET Syst. Biol. 1 2007 292 297
24. L. Li et al. The human phosphotyrosine signaling network: evolution and hotspots of hijacking in cancer Genome Res. 22 2012 1222 1230
25. D.F. Ransohoff, and M.L. Gourlay Sources of bias in specimens for research about molecular markers for cancer J. Clin. Oncol. 28 2010 698 704
26. R.D. Prasasya et al. Analysis of cancer signaling networks by systems biology to develop therapies Semin. Cancer Biol. 21 2011 200 206
27. J.E. Dancey, and H.X. Chen Strategies for optimizing combinations of molecularly targeted anticancer agents Nat. Rev. Drug Discov. 5 2006 649 659
28. P. Lecca, and C. Priami Biological network inference for drug discovery Drug Discov. Today 18 2013 256 264
29. C.T. Keith et al. Multicomponent therapeutics for networked systems Nat. Rev. Drug Discov. 4 2005 71 78
30. B. Schoeberl et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis Sci. Signal. 2 2009 ra31
31. M.J. Lee et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks Cell 149 2012 780 794
32. B.T. Hennessy et al. Exploiting the PI3K/AKT pathway for cancer drug discovery Nat. Rev. Drug Discov. 4 2005 988 1004
33. B. Di Ventura et al. From in vivo to in silico biology and back Nature 443 2006 527 533
34. M.J. Bissell, and D. Radisky Putting tumours in context Nat. Rev. Cancer 1 2001 46 54
35. R.A. Gatenby et al. Adaptive therapy Cancer Res. 69 2009 4894 4903
36. L.L. Campbell, and K. Polyak Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6 2007 2332 2338
37. N. Navin et al. Tumour evolution inferred by single-cell sequencing Nature 472 2011 90 94
38. Z. Wang et al. Discovering molecular targets in cancer with multiscale modeling Drug Dev. Res. 72 2011 45 52
39. Z. Wang et al. Cross-scale, cross-pathway evaluation using an agent-based non-small cell lung cancer model Bioinformatics 25 2009 2389 2396
40. Z. Wang et al. Simulating non-small cell lung cancer with a multiscale agent-based model Theor. Biol. Med. Model. 4 2007 50
41. T. Dittmar et al. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR FASEB J. 16 2002 1823 1825
42. S.D. Santos et al. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate Nat. Cell. Biol. 9 2007 324 330
43. Z. Wang et al. Cross-scale sensitivity analysis of a non-small cell lung cancer model: linking molecular signaling properties to cellular behavior Biosystems 92 2008 249 258
44. Z. Wang et al. Identifying therapeutic targets in a combined EGFR-TGFbetaR signalling cascade using a multiscale agent-based cancer model Math. Med. Biol. 29 2012 95 108
45. Z. Wang et al. Identification of critical molecular components in a multiscale cancer model based on the integration of Monte Carlo, resampling, and ANOVA Front. Physiol. 2 2011 35
46. W. Materi, and D.S. Wishart Computational systems biology in drug discovery and development: methods and applications Drug Discov. Today 12 2007 295 303
47. R.L. Winslow et al. Computational medicine: translating models to clinical care Sci. Transl. Med. 4 2012 158rv111
48. P.H. van der Graaf, and N. Benson Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development Pharm. Res. 28 2011 1460 1464
49. J.C. Sible, and J.J. Tyson Mathematical modeling as a tool for investigating cell cycle control networks Methods 41 2007 238 247
50. S. Dudoit et al. Comparison of discrimination methods for the classification of tumors using gene expression data J. Am. Statist. Assoc. 97 2002 77 87
51. P.A. Silver, and J.C. Way Molecular systems biology in drug development Clin. Pharmacol. Ther. 82 2007 586 590
52. J.H. Brown, and G.B. West Scaling in Biology 2000 Oxford University Press
53. G.B. West et al. A general model for the origin of allometric scaling laws in biology Science 276 1997 122 126
54. J.R. Banavar et al. A general basis for quarter-power scaling in animals Proc. Natl. Acad. Sci. U. S. A. 107 2010 15816 15820
55. J.P. DeLong et al. Shifts in metabolic scaling, production, and efficiency across major evolutionary transitions of life Proc. Natl. Acad. Sci. U. S. A. 107 2010 12941 12945
56. C. Guiot et al. Does tumor growth follow a universal law? J. Theor. Biol. 225 2003 147 151
57. M. Egeblad et al. Tumors as organs: complex tissues that interface with the entire organism Dev. Cell 18 2010 884 901
58. R.K. Jain Delivery of novel therapeutic agents in tumors: physiological barriers and strategies J. Natl. Cancer Inst. 81 1989 570 576
59. B.C. Baguley Multiple drug resistance mechanisms in cancer Mol. Biotechnol. 46 2010 308 316
60. H.B. Frieboes et al. Three-dimensional multispecies nonlinear tumor growth - II: tumor invasion and angiogenesis J. Theor. Biol. 264 2010 1254 1278